TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based...
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
About this item
Full title
Author / Creator
Oden-Gangloff, A , Di Fiore, F , Bibeau, F , Lamy, A , Bougeard, G , Charbonnier, F , Blanchard, F , Tougeron, D , Ychou, M , Boissière, F , Le Pessot, F , Sabourin, J-C , Tuech, J-J , Michel, P and Frebourg, T
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Recent studies have suggested that activation of the EGFR pathway leads to malignant transformation only if the p53 protein is inactivated. Therefore, we evaluated the impact of
TP53
mutations on cetuximab-based chemotherapy (CT) sensitivity in combination with
KRAS
mutations that have been associated with cetuximab resistance.
KRAS<...
Alternative Titles
Full title
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2676556
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2676556
Other Identifiers
ISSN
0007-0920,1532-1827
E-ISSN
1532-1827
DOI
10.1038/sj.bjc.6605008
